Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared on LinkedIn:
“Our Q3 R&D progress reflects the work underway to advance potential medicines and vaccines for patients across Oncology, Internal Medicine, Vaccines and Inflammation and Immunology.
This quarter included two regulatory decisions, one pivotal readout and eight key pivotal study starts, alongside data presented at several medical congresses.
Late-stage programs are advancing in all four areas, with new pivotal studies adding depth to our pipeline.
Our progress reflects the focus and work of colleagues across Pfizer R&D.
With important milestones ahead, we will keep applying that same discipline to advance the strongest science for patients globally.”
R&D Highlights
Momentum across a deep, diversified pipeline.
Delivering on Critical R&D Milestones
2026 Accomplishments to Date
- 16 Key Phase 3 Study Starts
- 7 Key Pivotal Data Readouts
- 5 Key Regulatory Approvals
Since August 4, 2026
8 Key Phase 3 Study Starts
- Atopic Dermatitis (x2); Asthma
- Weekly CWM (China); Weekly and Monthly CWM (Japan)
- Chronic Migraine
- Moderate Alopecia Areata
1 Pivotal Data Readout
Relapsed/Refractory Multiple Myeloma (MagnetisMM-32)
2 Key Regulatory Approvals
- 1L HER2+ Metastatic Breast Cancer Maintenance (HER2CLIMB-05)
- 1L HRRm Metastatic Hormone-Sensitive Prostate Cancer (TALAPRO-3)
“Pfizer’s R&D engine is delivering progress across all four of our therapeutic areas.
We are putting our resources behind the opportunities with the greatest potential for patients, and we are advancing them as quickly as the science allows. We expect a strong cadence of regulatory decisions, data readouts and pivotal study starts over the next twelve months” – Chris Boshoff, Chief Scientific Officer and President, R&D.
93 R&D Projects in Development
- 31 – PHASE 1
- 24 – PHASE 2
- 32 – PHASE 3
- 2 – REGISTRATION
Spanning four therapeutic areas։
- Oncology
- Vaccines
- Internal Medicine
- Inflammation and Immunology
Learn more about our potential breakthroughs in the making։ Potential Breakthroughs in the Making․”
Other articles about Pfizer on OncoDaily.